Jim Simons
MLYS icon

Jim Simons’s Mineralys Therapeutics MLYS Stock Holding History

Jim Simons’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
382,800
+60,700
+19% +$1.78M 0.02% 950
2025
Q4 		$11.7M Buy
322,100
+274,700
+580% +$11M 0.02% 841
2025
Q3 		$1.8M Sell
47,400
-129,526
-73% -$2.8M ﹤0.01% 2142
2025
Q2 		$2.39M Sell
176,926
-374
-0.2% -$5.42K ﹤0.01% 2001
2025
Q1 		$2.82M Buy
177,300
+57,800
+48% +$665K ﹤0.01% 1781
2024
Q4 		$1.47M Buy
119,500
+15,700
+15% +$205K ﹤0.01% 2258
2024
Q3 		$1.26M Buy
103,800
+42,000
+68% +$508K ﹤0.01% 2308
2024
Q2 		$723K Buy
61,800
+30,100
+95% +$379K ﹤0.01% 2504
2024
Q1 		$409K Buy
31,700
+6,200
+24% +$76.6K ﹤0.01% 2951
2023
Q4 		$219K Sell
25,500
-70,190
-73% -$551K ﹤0.01% 3105
2023
Q3 		$910K Buy
+95,690
New +$1.25M ﹤0.01% 2375

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jim Simons's MLYS Position: Q1 2026 in Review

Jim Simons increased its Mineralys Therapeutics (MLYS) stake by 19% in Q1 2026, buying an estimated $1.78M and bringing the position to 382,800 shares worth $10.4M. The position accounts for 0.02% of the portfolio, ranked #950.

Jim Simons first reported a position in MLYS in Q3 2023 and has held it in 11 quarters since. The position peaked at $11.7M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Jim Simons held 382,800 shares of Mineralys Therapeutics worth $10.4M as of Q1 2026.
  • Jim Simons bought 60,700 Mineralys Therapeutics shares in Q1 2026, an estimated $1.78M.
  • Mineralys Therapeutics made up 0.02% of Jim Simons's portfolio in Q1 2026, its #950 holding.
  • Jim Simons first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Jim Simons's Mineralys Therapeutics position peaked at $11.7M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.